Relmada Therapeutics (RLMD) 10-Q 15 May 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Mar. 31, 2019	May 14, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	RELMADA THERAPEUTICS, INC.
Entity Central Index Key	0001553643
Trading Symbol	RLMD
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		33,256,987

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2019	Jun. 30, 2018
Current assets:
Cash and cash equivalents	$ 2,053,853	$ 2,238,943
Other receivable		7,617
Lease payments receivable - short-term	68,654	64,486
Prepaid expenses	207,793	426,921
Total current assets	2,330,300	2,737,967
Fixed assets, net of accumulated depreciation	8,298	12,080
Other assets	43,908	24,788
Lease payments receivable - long-term	221,221	273,244
Total assets	2,603,727	3,048,079
Current liabilities:
Accounts payable	1,080,110	765,439
Accrued expenses	1,020,950	659,455
Notes payable	28,769	285,170
Derivative liabilities		4,194,634
Total current liabilities	2,129,829	5,904,698
Promissory notes payable, net of discount of $0 and $4,548,543		2,656,457
Total liabilities	2,129,829	8,561,155
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock
Common stock, $0.001 par value,200,000,000 shares authorized, 30,980,658 and 12,549,870 shares issued and outstanding, respectively	30,981	12,550
Additional paid-in capital	107,982,692	88,818,681
Accumulated deficit	(107,539,775)	(94,344,307)
Total stockholders' equity (deficit)	473,898	(5,513,076)
Total liabilities and stockholders' equity (deficit)	2,603,727	3,048,079
Class A Convertible Preferred Stock
Stockholders' equity (deficit):
Preferred stock

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Mar. 31, 2019	Jun. 30, 2018
Promissory notes payable, net of discount	$ 0	$ 4,548,543
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	200,000,000	200,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	30,980,658	12,549,870
Common stock, shares outstanding	30,980,658	12,549,870
Class A convertible preferred stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	3,500,000	3,500,000
Preferred stock, shares issued
Preferred stock, shares outstanding

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Operating expenses:
Research and development	$ 1,275,948	$ 1,666,902	$ 3,954,848	$ 1,983,372
General and administrative	1,426,056	883,009	4,637,370	3,003,980
Total Operating Expenses	2,702,004	2,549,911	8,592,218	4,987,352
Loss from Operations	(2,702,004)	(2,549,911)	(8,592,218)	(4,987,352)
Other income (expenses):
Change in fair value of derivative liabilities		(254,862)	(54,634)	80,542
Loss on extinguishment of debt			(3,774,468)
Interest income (expense), net	15,939	(397,111)	(774,148)	(706,460)
Other income				2,350
Total other income (expenses)	15,939	(651,973)	(4,603,250)	(623,568)
Net loss	$ (2,686,065)	$ (3,201,884)	$ (13,195,468)	$ (5,610,920)
Loss per common share - basic and diluted	$ (0.09)	$ (0.26)	$ (0.58)	$ (0.45)
Weighted average number of common shares outstanding - basic and diluted	30,037,971	12,547,620	22,670,534	12,542,678

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities
Net loss	$ (13,195,468)	$ (5,610,920)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	3,782	1,698
Stock-based compensation	810,537	365,173
Amortization of deferred financing costs	661,167	501,203
Change in fair value of derivative liabilities	54,634	(80,542)
Fair value of shares relinquished in litigation	(394,410)
Loss on promissory note extinguishment	3,774,468
Changes in operating assets and liabilities:
Other receivable	7,617	232,597
Other assets	(19,120)
Lease payment receivable	47,855	44,022
Prepaid expenses	219,128	312,572
Accounts payable	314,671	483,531
Accrued expenses	884,365	14,761
Net cash used in operating activities	(6,830,774)	(3,735,905)
Cash flows from investing activities
Purchase of fixed assets		(2,591)
Net cash used in investing activities		(2,591)
Cash flows from financing activities
Proceeds from promissory notes and warrants, net of fees		6,534,400
Principal payments of notes payable	(256,401)	(248,790)
Net proceeds from sale of units	6,902,085
Net cash provided by financing activities	6,645,684	6,285,610
Net (decrease) increase in cash and cash equivalents	(185,090)	2,547,114
Cash and cash equivalents at beginning of the period	2,238,943	1,710,512
Cash and cash equivalents at end of the period	2,053,853	4,257,626
Cash paid during the period for:
Income taxes
Interest	5,876	2,738
Non-cash investing and financing transactions:
Issuances of common stock resulting from cashless exercise of warrants		17
Issuance of vested shares of restricted stock		38
Warrants issued to placement agent		200,658
Warrants issued to promissory note holders		1,268,813
Derivative associated with issuance of promissory notes		3,862,095
Debt issuance cost from accrued financing fees		127,757
Write-off of derivative liability due to adoption of ASU 2017-11	59,397
Conversion of promissory notes and accrued interest to common stock	$ 8,030,365

Statements of Stockholders' Equ

Statements of Stockholders' Equity (Unaudited) - USD ($)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Beginning Balance at Jun. 30, 2017	$ 12,528	$ 86,831,211	$ (85,383,455)	$ 1,460,284
Beginning Balance, shares at Jun. 30, 2017	12,528,374
Issuance of warrants to promissory notes payable placement agent		75,577		75,577
Issuance of warrants to holders of promissory notes payable		841,617		841,617
Issuance of common stock on exercise of Series A Preferred Stock Warrants	$ 17	(17)		16,746
Issuance of common stock on exercise of Series A Preferred Stock Warrants, shares	16,746
Stock-based compensation		68,870		68,870
Net loss			(981,686)	(981,686)
Ending Balance at Sep. 30, 2017	$ 12,545	87,817,258	(86,365,141)	1,464,662
Ending Balance, shares at Sep. 30, 2017	12,545,120
Beginning Balance at Jun. 30, 2017	$ 12,528	86,831,211	(85,383,455)	1,460,284
Beginning Balance, shares at Jun. 30, 2017	12,528,374
Net loss				(5,610,920)
Ending Balance at Mar. 31, 2018	$ 12,548	88,665,834	(90,994,375)	(2,315,993)
Ending Balance, shares at Mar. 31, 2018	12,548,870
Beginning Balance at Sep. 30, 2017	$ 12,545	87,817,258	(86,365,141)	1,464,662
Beginning Balance, shares at Sep. 30, 2017	12,545,120
Issuance of warrants to promissory notes payable placement agent		125,081		125,081
Issuance of warrants to holders of promissory notes payable		424,727		424,727
Stock-based compensation		134,038		134,038
Net loss			(1,427,350)	(1,427,350)
Ending Balance at Dec. 31, 2017	$ 12,545	88,501,104	(87,792,491)	721,158
Ending Balance, shares at Dec. 31, 2017	12,545,120
Issuance of warrants to holders of promissory notes payable		2,469
Stock-based compensation		162,265		162,265
Issuance of restricted stock	$ 4	(4)
Issuance of restricted stock, shares	3,750
Net loss			(3,201,884)	(3,201,884)
Ending Balance at Mar. 31, 2018	$ 12,548	88,665,834	(90,994,375)	(2,315,993)
Ending Balance, shares at Mar. 31, 2018	12,548,870
Beginning Balance at Jun. 30, 2018	$ 12,550	88,818,681	(94,344,307)	(5,513,076)
Beginning Balance, shares at Jun. 30, 2018	12,549,870
Cumulative effect of write-off of derivative liability for adoption of ASU 2017-11		59,397		59,397
Adjusted Balances as at June 30, 2018	$ 12,550	88,878,078	(94,344,307)	(5,453,679)
Adjusted Balances as at June 30, 2018, shares	12,549,870
Stock-based compensation		152,801		152,801
Net loss			(3,380,093)	(3,380,093)
Ending Balance at Sep. 30, 2018	$ 12,550	89,030,879	(97,724,400)	(8,680,971)
Ending Balance, shares at Sep. 30, 2018	12,549,870
Beginning Balance at Jun. 30, 2018	$ 12,550	88,818,681	(94,344,307)	(5,513,076)
Beginning Balance, shares at Jun. 30, 2018	12,549,870
Net loss				(13,195,468)
Ending Balance at Mar. 31, 2019	$ 30,981	107,982,692	(107,539,775)	473,898
Ending Balance, shares at Mar. 31, 2019	30,980,658
Beginning Balance at Sep. 30, 2018	$ 12,550	89,030,879	(97,724,400)	(8,680,971)
Beginning Balance, shares at Sep. 30, 2018	12,549,870
Stock-based compensation		263,044		263,044
Conversion of Notes and accrued interest	$ 10,731	11,794,102		11,804,833
Conversion of Notes and accrued interest, shares	10,731,669
Equity units issued for cash	$ 6,483	5,170,602		5,177,085
Equity units issued for cash, shares	6,482,671
Net loss			(7,129,310)	(7,129,310)
Ending Balance at Dec. 31, 2018	$ 29,764	106,258,627	(104,853,710)	1,434,681
Ending Balance, shares at Dec. 31, 2018	29,764,210
Stock-based compensation		394,692		394,692
Equity units issued for cash	$ 1,520	1,723,480		1,725,000
Equity units issued for cash, shares	1,519,840
Shares relinquished	$ (303)	(394,107)		(394,410)
Shares relinquished, shares	(303,392)
Net loss			(2,686,065)	(2,686,065)
Ending Balance at Mar. 31, 2019	$ 30,981	$ 107,982,692	$ (107,539,775)	$ 473,898
Ending Balance, shares at Mar. 31, 2019	30,980,658

Business

Business	9 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BUSINESS	NOTE 1 – BUSINESS Relmada Therapeutics, Inc. ("Relmada" or the "Company") (a Nevada corporation), is a clinical-stage, publicly traded biotechnology company focused on the development of d-methadone (dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. d-Methadone is a new chemical entity that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. REL-1017 is in Phase 2 for the treatment of major depressive disorder. The Company has a portfolio of three 505b2 product candidates at various stages of development. These products are: LevoCap ER (REL-1015), an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab (oral buprenorphine, REL-1028), an oral dosage form of the opioid analgesic buprenorphine; and MepiGel (topical mepivacaine, REL-1021), an orphan drug designated topical formulation of the local anesthetic mepivacaine. These products are not currently in active development. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company's research and development will be successfully completed or that any product will be approved or commercially viable. The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with the FDA and other governmental regulations and approval requirements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim unaudited consolidated financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete consolidated financial statements. The unaudited consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended June 30, 2018 and notes thereto contained in the Company’s Annual Report on Form 10-K. Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the twelve month period following the issuance of these consolidated financial statements. As shown in the accompanying financial statements, the Company incurred negative operating cash flows of $6,830,774 for the nine months ended March 31, 2019 and accumulated deficit of $107,539,775 from inception through March 31, 2019. These conditions raise doubt as to the Company’s ability to continue as a going concern for one year after the date the financial statements are issued. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. We will need to raise additional funds in order to continue our clinical trials. Insufficient funds may cause us to delay, reduce the scope of or eliminate one or more of our development programs. Our future capital needs and the adequacy of our available funds will depend on many factors, including the cost of clinical studies and other actions needed to obtain regulatory approval of our products in development. Management plans to raise additional funds through public or private sales of equity or debt securities or from bank or other loans or through strategic collaboration and/or licensing agreements, to fund operations until the Company is able to generate enough revenues to cover operating costs. Financing may not be available on acceptable terms, or at all, and our failure to raise capital when needed could materially adversely impact our growth plans and our financial condition or results of operations. Additional equity financing, if available, may be dilutive to our shareholders. In addition, the Company may never be able to generate sufficient revenue if any from its potential products. Principles of Consolidation The unaudited consolidated financial statements include the Company’s accounts and those of the Company’s wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. The significant estimates are the valuation of derivative liabilities, stock-based compensation expenses and recorded amounts related to income taxes. Cash and Cash Equivalents The Company considers cash deposits and all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company’s cash deposits are held at two high-credit-quality financial institutions. The Company’s cash deposits at these institutions exceed federally insured limits. Patents Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain. Fixed Assets Fixed assets are stated at cost less accumulated depreciation. Fixed assets are comprised of computers and software, leasehold improvements, and furniture and fixtures. Depreciation is calculated using the straight-line method over the estimated useful life of the assets. Computers and software have an estimated useful life of three years. Furniture and fixtures have an estimated useful life of approximately seven years. Fair Value of Financial Instruments The Company’s financial instruments primarily include cash, accounts payable and notes payable. Due to the short-term nature of cash, accounts payable and notes payable the carrying amounts of these assets and liabilities approximate their fair value. Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows: Level 1 Inputs - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 Inputs - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means. Level 3 Inputs - Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity). Fair Value on a Recurring Basis As required by Accounting Standard Codification (“ASC”) Topic No. 820 - 10 Fair Value Measurement Income Taxes The Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future deductibility is uncertain. As of March 31, 2019 and June 30, 2018, the Company had recognized a valuation allowance to the full extent of the Company’s net deferred tax assets since the likelihood of realization of the benefit does not meet the more likely than not threshold. The Company files a U.S. Federal income tax return and, various state returns. Uncertain tax positions taken on the Company’s tax returns will be accounted for as liabilities for unrecognized tax benefits. The Company will recognize interest and penalties, if any, related to unrecognized tax benefits in general and administrative expenses in the statements of operations. There were no liabilities recorded for uncertain tax positions at March 31, 2019 and June 30, 2018. The open tax years, subject to potential examination by the applicable taxing authority, for the Company are from June 30, 2015 through June 30, 2018. Research and Development Research and development costs primarily consist of research contracts for the advancement of product development, salaries and benefits, stock-based compensation, and consultants. The Company expenses all research and development costs in the period incurred. The Company makes an estimate of costs in relation to clinical study contracts. The Company analyzes the progress of studies, including the progress of clinical studies and phases, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Stock-Based Compensation The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which an employee is required to provide service in exchange for the award - the requisite service period. The grant-date fair value of employee share options is estimated using the Black-Scholes option pricing model adjusted for the unique characteristics of those instruments. Compensation expense for warrants granted to non-employees is determined by the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured, and is recognized over the service period. The Company reviews its agreements and the future performance obligation with respect to the unvested warrants for its vendors or consultants. When appropriate, the Company will expense the unvested warrants at the time when management deems the service obligation for future services has ceased. Loss per Common Share Basic loss per common share attributable to common stockholders is calculated by dividing the loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted loss per common share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of restricted stock awards, options and warrants to purchase common stock. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. For the nine months ended March 31, 2019 and 2018, the following potentially dilutive securities were excluded from the computation of diluted net loss per share, as the inclusion of such shares would be anti-dilutive: Nine months ended March 31, March 31, Stock options 5,743,240 2,573,240 Common stock warrants 16,047,775 9,816,025 Total 21,791,015 12,389,265 Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842), whereby lessees will be required to recognize for all leases at the commencement date a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. The new standard is effective for us on July 1, 2019. with early adoption permitted. We expect to adopt the new standard on its effective date. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1) its effective date or (2) the beginning of the earliest comparative period presented in the financial statements as its date of initial application. If an entity chooses the second option, the transition requirements for existing leases also apply to leases entered into between the date of initial application and the effective date. The entity must also recast its comparative period financial statements and provide the disclosures required by the new standard for the comparative periods. We expect to adopt the new standard on July 1, 2019 and use the effective date as our date of initial application. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before July 1, 2019. The Company is still evaluating the expected impact on its financials. In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share Distinguishing Liabilities from Equity Derivatives and Hedging Accounting for Certain Financial Instruments with Down Round Features. In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting

Prepaid Expenses

Prepaid Expenses	9 Months Ended
	Mar. 31, 2019
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
PREPAID EXPENSES	NOTE 3 – PREPAID EXPENSES Prepaid expenses consisted of the following (rounded to nearest $00): March 31, June 30, Rent $ - $ 9,200 Research and development - 20,800 Insurance 115,200 345,700 Legal 12,100 10,000 Other 80,500 41,200 Total $ 207,800 $ 426,900

Fixed Assets

Fixed Assets	9 Months Ended
	Mar. 31, 2019
Property, Plant and Equipment [Abstract]
FIXED ASSETS	NOTE 4 – FIXED ASSETS Fixed assets, net of accumulated depreciation, consisted of the following (rounded to nearest $00): Useful lives March 31, June 30, Computer and software 3 years $ 16,700 $ 16,700 Less: accumulated depreciation (8,400 ) (4,600 ) Fixed assets $ 8,300 $ 12,100

Accrued Expenses

Accrued Expenses	9 Months Ended
	Mar. 31, 2019
Payables and Accruals [Abstract]
ACCRUED EXPENSES	NOTE 5 – ACCRUED EXPENSES Accrued expenses consisted of the following (rounded to nearest $00): March 31, June 30, Research and development $ 9,700 $ 10,400 Professional fees 132,900 173,600 Interest on promissory notes - 371,600 Accrued vacation 77,800 48,000 Litigation settlement, net 750,000 - Other 50,600 55,900 Total $ 1,021,000 $ 659,500

Notes Payable

Notes Payable	9 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 6 – NOTES PAYABLE In June 2018, the Company entered into a note for approximately $285,200 in conjunction with a renewal of its director and officer insurance policy. The interest rate was 2.35% per annum. The note matured on April 9, 2019. At March 31, 2019 and June 30, 2018, the note payable outstanding balances were approximately $28,800 and $285,200, respectively.

Derivative Liabilities

Derivative Liabilities	9 Months Ended
	Mar. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE LIABILITIES	NOTE 7 – DERIVATIVE LIABILITIES ASC Topic No. 815 – Derivatives and Hedging At March 31, 2019 and June 30, 2018, the Company had warrants resulting from equity offerings in May 2014 and June 2014 that do not have fixed settlement provisions because their exercise prices may be lowered if the Company issues securities at lower prices in the future, the Company concluded that the instruments are not indexed to the Company's stock. Until September 30, 2018, the Company followed ASC Topic No 815 and treated the warrants as derivative liabilities. In determining the fair value of the derivative liabilities, the Company used the Black-Scholes option pricing model at September 30 and June 30, 2018. As noted in Note 2, the Company elected to early adopt ASU 2017-11 and reversed the derivative liability into equity effective July 1, 2018. The warrants balance of $59,397 was reversed to equity effective July 1, 2018. The following is a summary of the assumptions used in the valuation model at June 30, 2018: June 30, 2018 Common stock issuable upon exercise of warrants 2,574,570 Market value of common stock on measurement date $ 1.01 Exercise price $7.50 and $11.25 Risk free interest rate (1) 2.33 % Expected life in years $ 0.95 Expected volatility (2) 102 % Expected dividend yields (3) None (1) The risk-free interest rate was determined by management using the applicable Treasury Bill as of the measurement date. (2) The historical trading volatility was determined by calculating the volatility of the Company's stock. (3) The Company does not expect to pay a dividend in the foreseeable future. Until October 18, 2018, the Company had promissory notes with a redemption feature that was not clearly and closely related to the host instrument and therefore is considered an embedded derivative which was bifurcated and recorded as a derivative liability. In determining the fair value of the derivative liabilities, the Company used the Monte-Carlo pricing model. The assumptions used in the valuation model considers the probability of redemption, the length of time to maturity and value of the redemption feature. On October 12 and 18, 2018, the Company conducted closings on its private placement of securities. As a result of these closings, the outstanding promissory notes converted into common stock. The redemption feature associated with the promissory notes was valued on October 18, 2018 using the Black-Scholes model. The change in value of the derivative between October 1, 2018 and the October 18, 2018 was recorded as income. The notes were converted to common stock on October 18, 2018. The Company had no financial liabilities accounted for at fair value on a recurring basis as of March 31, 2019. The following table sets forth, by level within the fair value hierarchy, the Company's financial liabilities that were accounted for at fair value on a recurring basis as of June 30, 2018: Markets for Other Significant Carrying Description (Level 1) (Level 2) (Level 3) 2018 Derivative liability – warrant instruments $ - $ - $ 30,526 $ 30,526 Derivative liabilities – embedded redemption feature of promissory notes - - 4,164,108 4,164,108 $ - $ - $ 4,194,634 $ 4,194,634 The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as level 3 in the fair value hierarchy for the nine months ended March 31, 2019 and 2017: Nine months ended March 31, March 31, 2019 2018 Beginning balance $ 4,194,634 $ 175,853 Adoption of ASU 2017-11 – warrants (59,397 ) - Fair value of derivative liabilities for redemption feature of promissory notes payable - 3,862,095 Change in fair value of derivative liabilities 54,634 (80,542 ) Extinguishment of derivative liabilities on conversion of promissory notes. (4,189,871 ) - Ending balance $ - $ 3,957,406

Promissory Notes Payable

Promissory Notes Payable	9 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
PROMISSORY NOTES PAYABLE	NOTE 8 – PROMISSORY NOTES PAYABLE Between September 2017 and January 2018, the Company issued two-year Convertible Promissory Notes (the "Notes") and warrants, for aggregate gross proceeds of $7,205,000, $6,534,400 net of direct debt issuance costs. The notes had an interest rate of 7% per annum. As a result of financings in October 2018, the principal and accumulated interest on the Convertible Promissory Notes was automatically converted into 10,731,669 shares of its common stock in accordance with the terms of the Notes. This resulted in a loss on extinguishment of debt, a non cash item, of approximately $3,774,500 in the quarter ended December 31, 2018.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Mar. 31, 2019
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY	NOTE 9 – STOCKHOLDERS' EQUITY Common Stock During the nine months ended March 31, 2019, the Company closed on private placements of securities pursuant to Unit Purchase Agreements and Subscription Agreements, each dated as shown below. The price per unit (comprising one common stock and a warrant to purchase 0.65 common stock) was $0.90. The Company issued an aggregate of 7,288,225 shares of common stock to investors in these closings, for net proceeds of $5,941,547. Date of closing Common Stock Issued Warrants issued Unit Price Net proceeds October 12, 2018 2,004,106 1,302,669 $ 0.90 $ 1,630,991 October 18, 2018 1,640,334 1,066,218 $ 0.90 $ 1,287,007 November 2, 2018 1,499,456 974,645 $ 0.90 $ 1,215,242 December 5, 2018 1,338,775 870,200 $ 0.90 $ 1,083,307 February 12, 2019 805,554 523,610 $ 0.90 $ 725,000 Total 7,288,225 4,737,342 $ 5,941,547 The exercise price of each warrant issued to investors was $1.50 with a 5-year term. Approximately $40,000 of legal costs were incurred that were not allocated to the individual closings. In addition to the above, on March 27, 2019, the Company closed on a private placement of securities pursuant to Unit Purchase Agreements and Subscription Agreements dated March 27, 2019. The price per unit of the March 27, 2019 Units (comprising one common stock and a warrant to purchase 0.50 common stock) was $1.40. The Company issued an aggregate of 714,285 shares of common stock and 357,142 warrants to investors in these closings, for net proceeds of $1,000,000. The exercise price of the March 27, 2019 warrants was $2.25. The October 12, 2018 and October 18, 2018 financings represented an Equity Financing as defined in the Convertible Promissory Note agreement. As a result of the , the Company's outstanding 7% Convertible Promissory Notes and accumulated interest converted into 10,731,669 shares of common stock. Placement Agent Warrants During the nine months ended March 31, 2019, the Company additionally issued an aggregate of 854,334 warrants to the placement agent in connection with the closings. The agent warrants have an exercise price of $0.99, are non-cancellable, vest upon issuance and expire on the fifth anniversary of the warrant date of issuance. Options In December 2014, the Board of Directors adopted and the shareholders approved Relmada's 2014 Stock Option and Equity Incentive Plan, as amended (the "Plan"), which allows for the granting of common stock awards, stock appreciation rights, and incentive and nonqualified stock options to purchase shares of the Company's common stock to designated employees, non-employee directors, and consultants and advisors. The Plan allowed for the granting of 1,611,769 options or stock awards. In August 2015, the board approved an amendment to the Plan. Among other things, the Plan Amendment updates the definition of "change of control" and provides for accelerated vesting of all awards granted under the plan in the event of a change of control of the Company. In January 2017, the stockholders approved an increase of 2,500,000 shares authorized to be issued under the Plan, raising the total shares allowed under the Plan to 4,111,768. In December 2017 the board approved, and in February 2018 the shareholders approved, an amendment to the Plan that increased the number of shares of common stock authorized for issuance under the Plan by an additional 2,500,000 shares from 4,111,768 to 6,611,768. In December 2018 the Board of Directors approved an amendment to the Plan to increase the number of shares of common stock authorized for issuance under the Plan by an additional 4,000,000 shares from 6,611,768 to 10,611,768. Stock options are exercisable generally for a period of 10 years from the date of grant and generally vest over four years. As of March 31, 2019, 4,868,528 shares were available for future grants under the Plan. As of March 31, 2019, no stock appreciation rights have been issued. The Company utilizes the Black-Scholes option pricing model to estimate the fair value of stock options and warrants. The price of common stock prior to the Company being public was determined from a third party valuation. The risk-free interest rate assumptions were based upon the observed interest rates appropriate for the expected term of the equity instruments. The expected dividend yield was assumed to be zero as the Company has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future. The expected volatility was based on historical volatility. The Company routinely reviews its calculation of volatility changes in future volatility, the Company's life cycle, its peer group, and other factors. The Company uses the simplified method for share-based compensation to estimate the expected term for employee option awards for share-based compensation in its option-pricing model. Prior to the adoption of ASU 2018-07 on October 1, 2018, the Company used the contractual term for non-employee options to estimate the expected term, for share-based compensation in its option-pricing model. On February 13, 2017, Mr. Michael Becker, the Company's Chief Financial Officer, resigned and entered into a consulting agreement with the Company to provide financial, investor, digital media, and public relations services for the Company. As a result of Mr. Becker's change from an employee to a consultant, his options and shares of restricted stock outstanding on such date continued to vest pursuant to the awards' original terms and were reclassified as non-employee awards. On December 15, 2017 Mr. Becker's consulting agreement expired and all unvested options were cancelled. On December 20, 2018, the Company awarded a total of 2,700,000 options to its chief executive officer, chief medical officer and board members with exercise price of $1.15 and a 10-year term vesting over 4-year period. The options have an aggregate fair value of $2.5 million calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 2.69% (2) expected life of 6.25 years, (3) expected volatility of 102.3%, and (4) zero expected dividends. At March 31, 2019, the Company has unrecognized stock-based compensation expense of approximately $3,448,900 related to unvested stock options over the weighted average remaining service period of 3.35 years. Options A summary of the changes in options during the nine months ended March 31, 2019 is as follows: Number Weighted Average Exercise Price For Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Outstanding and expected to vest at June 30, 2018 3,068,865 $ 1.45 8.8 $ 511,000 Forfeited (25,625 ) $ 7.59 - $ - Issued 2,700,000 $ 1.15 9.7 $ 1,674,000 Outstanding and expected to vest at March 31, 2019 5,743,240 $ 1.28 8.9 $ 4,199,110 Options exercisable at March 31, 2019 1,278,687 $ 2.22 7.6 $ 799,763 Warrants A summary of the changes in outstanding warrants during the nine months ended March 31, 2019 is as follows: Number of Shares Weighted Average Exercise Price Per Share Outstanding and vested at June 30, 2018 9,815,025 $ 3.96 Forfeited (7,500 ) 4.00 Issued 6,240,247 1.46 Outstanding and vested at March 31, 2019 16,047,772 $ 2.15 Included in the warrants outstanding at June 30, 2018, and March 31, 2019 are 2,574,570 warrants with an exercise price that is subject to downward adjustment on the sale of equity at prices below their original exercise price. The issuance of common stock in the three months ended March 31, 2019 resulted in a reduction of the exercise price of these warrants. This reduction had a di minimis effect on the financial statements. On December 20, 2018, the Company granted 100,000 warrants to a contractor with exercise price of $1.15, a 10-year term and immediate vesting. The warrants have an aggregated fair value of $93,762 that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 2.69% (2) expected life of 6.25 years, (3) expected volatility of 102.3%, and (4) zero expected dividends. On January 1, 2019, the Company granted 120,000 warrants to a contractor with exercise price of $1.15, a 10-year term and quarterly vesting over four years vesting. The warrants have an aggregated fair value of $112,183 that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 2.49% (2) expected life of 6.25 years, (3) expected volatility of 102.0%, and (4) zero expected dividends. On March 9, 2019, the Company granted 71,429 warrants to a consultant with exercise price of $1.75, a 5-year term and immediate vesting. The warrants have an aggregated fair value of $95,131 that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 2.42% (2) expected life of 5 years, (3) expected volatility of 102.0%, and (4) zero expected dividends. At March 31, 2019 and June 30, 2018, the aggregate intrinsic value of warrants vested and outstanding was approximately $4,057,000 and $215,000, respectively. The following summarizes the components of stock-based compensation expense which includes stock options in the consolidated statements of operations for the nine months ended March 31, 2019 and 2018 (rounded to nearest $00): Nine months ended March 31, Nine months ended March 31, Research and development $ 65,700 $ 44,500 General and administrative 744,800 320,700 Total $ 810,500 $ 365,200

Related Party Transactions

Related Party Transactions	9 Months Ended
	Mar. 31, 2019
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 10 – RELATED PARTY TRANSACTIONS Consulting Agreements On August 4, 2015, the Company entered into an Advisory and Consulting Agreement with Sandesh Seth, the Company's Chairman of the Board. The effective date of the consulting agreement is June 30, 2015. Mr. Seth has substantial experience in, among other matters, business development, corporate planning, corporate finance, strategic planning, investor relations and public relations, and an expansive network of connections spanning the biopharmaceutical industry, accounting, legal and corporate communications professions. Mr. Seth will provide advisory and consulting services to assist the Company with strategic advisory services, assist in prioritizing product development programs per strategic objectives, assist in recruiting of key personnel and directors, corporate planning, business development activities, corporate finance advice, and assist in investor and public relations services. In consideration for the services to be provided, the Company agreed to pay Mr. Seth $12,500 per month on an ongoing basis. On June 6, 2017, Mr. Seth resigned from the Company to focus his attention on matters external to Relmada. The Company agreed to continue its advisory and consulting arrangement with Mr. Seth until December 31, 2017. On June 12, 2017, the Company and Maged Shenouda, a director of the Company, entered into a Consulting Agreement. Pursuant to the terms of the agreement, Mr. Shenouda will assist the Company with matters that may be requested by the Company. Mr. Shenouda will be paid a consulting fee of $10,000 per month. The term of the agreement is for one year. On November 13, 2017, Mr. Shenouda and the Company agreed to terminate the Consulting Agreement effective December 31, 2017.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 11 – COMMITMENTS AND CONTINGENCIES Legal On February 6, 2019 the Company entered into a settlement agreement with Najib Babul, Relmada’s former President. Dr Babul relinquished his 303,392 shares in Relmada and signed a consulting contract and Relmada committed to a $500,000 initial payment and four subsequent payments of $250,000 on March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019. For accounting purposes no fair value was attributed to the consulting agreement. From time to time, the Company may become involved in lawsuits and other legal proceedings that arise in the course of business. Litigation is subject to inherent uncertainties, and it is not possible to predict the outcome of litigation with total confidence. The Company is currently not aware of any legal proceedings or potential claims against it whose outcome would be likely, individually or in the aggregate, to have a material adverse effect on the Company’s business, financial condition, operating results, or cash flows. Leases and Sublease The Company leased its corporate headquarters at 750 Third Avenue, 9th Floor, New York, New York 10017. The monthly rental fee was $9,454 per month. The lease was terminated effective January 1, 2019. Effective January 1, 2019, the Company entered a one year lease for its headquarters at 880 Third Avenue, 12 th On June 8, 2017, the Company entered into an Amended and Restated License Agreement with Actinium Pharmaceuticals, Inc. (“Actinium”). Pursuant to the terms of the agreement, Actinium will continue to license the furniture, fixtures, equipment and tenant improvements located in the office (“FFE”) for a license fee of $7,529 per month until December 8, 2022. Actinium shall have at any time during the term of this agreement the right to purchase the FFE for $496,914, less any previously paid license fees. The license of FFE qualifies as a sales-type lease. At inception, the Company derecognized the underlying assets of $493,452, recognized discounted lease payments receivable of $397,049 using the discount rate of 8.38% and recognized loss on sales-type lease of fixed assets of $96,403. As of March 31, 2019, the balance of unearned interest income was approximately $48,900. Contractual Obligations The following tables sets forth our contractual obligations for the next five years and thereafter: Total Less than 1 - 2 years 3 - 5 years More than Office lease $ 67,500 $ 67,500 $ - $ - $ - Note payable 28,800 28,800 - - - Total obligations $ 96,300 $ 96,300 $ - $ - $ -

Subsequent Events

Subsequent Events	9 Months Ended
	Mar. 31, 2019
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 12 – SUBSEQUENT EVENTS On April 1, 2019 the Company awarded 150,000 options to a new employee with exercise price of $1.76 and a 10-year term vesting over 4-year period. The options have an aggregate fair value of $213,803 calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 2.31% (2) expected life of 6.25 years, (3) expected volatility of 101.5%, and (4) zero expected dividends. On April 12, 2019, the Company filed a Certificate of Amendment to its Articles of Incorporation to increase the number of authorized shares of the Company’s common stock from 100,000,000 to 200,000,000 shares. On April 15, 2019, the Company executed an amendment to the Company’s 2014 Stock Option and Equity Incentive Plan. The amendment increases the number of shares of common stock that the Company is authorized to issue under the plan to 10,111,718 shares. On May 14, 2019, the Company closed on a private placement of securities pursuant to Unit Purchase Agreements and Subscription Agreements dated May 14, 2019. The price per unit of the May 14, 2019 Units (comprising one common stock and a warrant to purchase 0.50 common stock) was $1.50. The Company issued an aggregate of 2,276,329 shares of common stock and 1,138,161 warrants to investors in this closing, for net proceeds of approximately $3,106,000. The exercise price of the May 14, 2019 investor warrants was $2.25 and they have a term of five years. The Company additionally issued warrants to brokers who acted as co-placement agents with respect to the private placement. One agent received warrants to purchase 48,433 shares at an exercise price of $1.65 and the other agent a warrant to purchase 99,000 shares of common stock at an exercise price of $2.25. Both warrants have a term of 5 years. The warrants have aggregate fair value of $66,800 and $122,942 respectively, calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 2.26% (2) expected life of 5 years, (3) expected volatility of 101%, and (4) zero expected dividends.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim unaudited consolidated financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete consolidated financial statements. The unaudited consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended June 30, 2018 and notes thereto contained in the Company's Annual Report on Form 10-K.
Going Concern	Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the twelve month period following the issuance of these consolidated financial statements. As shown in the accompanying financial statements, the Company incurred negative operating cash flows of $6,830,774 for the nine months ended March 31, 2019 and accumulated deficit of $107,539,775 from inception through March 31, 2019. These conditions raise doubt as to the Company’s ability to continue as a going concern for one year after the date the financial statements are issued. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. We will need to raise additional funds in order to continue our clinical trials. Insufficient funds may cause us to delay, reduce the scope of or eliminate one or more of our development programs. Our future capital needs and the adequacy of our available funds will depend on many factors, including the cost of clinical studies and other actions needed to obtain regulatory approval of our products in development. Management plans to raise additional funds through public or private sales of equity or debt securities or from bank or other loans or through strategic collaboration and/or licensing agreements, to fund operations until the Company is able to generate enough revenues to cover operating costs. Financing may not be available on acceptable terms, or at all, and our failure to raise capital when needed could materially adversely impact our growth plans and our financial condition or results of operations. Additional equity financing, if available, may be dilutive to our shareholders. In addition, the Company may never be able to generate sufficient revenue if any from its potential products.
Principles of Consolidation	Principles of Consolidation The unaudited consolidated financial statements include the Company's accounts and those of the Company's wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. The significant estimates are the valuation of derivative liabilities, stock-based compensation expenses and recorded amounts related to income taxes.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers cash deposits and all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company's cash deposits are held at two high-credit-quality financial institutions. The Company's cash deposits at these institutions exceed federally insured limits.
Patents	Patents Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.
Fixed Assets	Fixed Assets Fixed assets are stated at cost less accumulated depreciation. Fixed assets are comprised of computers and software, leasehold improvements, and furniture and fixtures. Depreciation is calculated using the straight-line method over the estimated useful life of the assets. Computers and software have an estimated useful life of three years. Furniture and fixtures have an estimated useful life of approximately seven years.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company's financial instruments primarily include cash, accounts payable and notes payable. Due to the short-term nature of cash, accounts payable and notes payable the carrying amounts of these assets and liabilities approximate their fair value. Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows: Level 1 Inputs - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 Inputs - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means. Level 3 Inputs - Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).
Fair Value on a Recurring Basis	Fair Value on a Recurring Basis As required by Accounting Standard Codification ("ASC") Topic No. 820 - 10 Fair Value Measurement
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future deductibility is uncertain. As of March 31, 2019 and June 30, 2018, the Company had recognized a valuation allowance to the full extent of the Company's net deferred tax assets since the likelihood of realization of the benefit does not meet the more likely than not threshold. The Company files a U.S. Federal income tax return and, various state returns. Uncertain tax positions taken on the Company's tax returns will be accounted for as liabilities for unrecognized tax benefits. The Company will recognize interest and penalties, if any, related to unrecognized tax benefits in general and administrative expenses in the statements of operations. There were no liabilities recorded for uncertain tax positions at March 31, 2019 and June 30, 2018. The open tax years, subject to potential examination by the applicable taxing authority, for the Company are from June 30, 2015 through June 30, 2018.
Research and Development	Research and Development Research and development costs primarily consist of research contracts for the advancement of product development, salaries and benefits, stock-based compensation, and consultants. The Company expenses all research and development costs in the period incurred. The Company makes an estimate of costs in relation to clinical study contracts. The Company analyzes the progress of studies, including the progress of clinical studies and phases, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability.
Stock-Based Compensation	Stock-Based Compensation The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which an employee is required to provide service in exchange for the award - the requisite service period. The grant-date fair value of employee share options is estimated using the Black-Scholes option pricing model adjusted for the unique characteristics of those instruments. Compensation expense for warrants granted to non-employees is determined by the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured, and is recognized over the service period. The Company reviews its agreements and the future performance obligation with respect to the unvested warrants for its vendors or consultants. When appropriate, the Company will expense the unvested warrants at the time when management deems the service obligation for future services has ceased.
Loss per Common Share	Loss per Common Share Basic loss per common share attributable to common stockholders is calculated by dividing the loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted loss per common share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of restricted stock awards, options and warrants to purchase common stock. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. For the nine months ended March 31, 2019 and 2018, the following potentially dilutive securities were excluded from the computation of diluted net loss per share, as the inclusion of such shares would be anti-dilutive: Nine months ended March 31, March 31, Stock options 5,743,240 2,573,240 Common stock warrants 16,047,775 9,816,025 Total 21,791,015 12,389,265
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842), whereby lessees will be required to recognize for all leases at the commencement date a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. The new standard is effective for us on July 1, 2019. with early adoption permitted. We expect to adopt the new standard on its effective date. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1) its effective date or (2) the beginning of the earliest comparative period presented in the financial statements as its date of initial application. If an entity chooses the second option, the transition requirements for existing leases also apply to leases entered into between the date of initial application and the effective date. The entity must also recast its comparative period financial statements and provide the disclosures required by the new standard for the comparative periods. We expect to adopt the new standard on July 1, 2019 and use the effective date as our date of initial application. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before July 1, 2019. The Company is still evaluating the expected impact on its financials. In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share Distinguishing Liabilities from Equity Derivatives and Hedging Accounting for Certain Financial Instruments with Down Round Features. In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Schedule of anti-dilutive securities	Nine months ended March 31, March 31, Stock options 5,743,240 2,573,240 Common stock warrants 16,047,775 9,816,025 Total 21,791,015 12,389,265

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	9 Months Ended
	Mar. 31, 2019
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of prepaid expenses	March 31, June 30, Rent $ - $ 9,200 Research and development - 20,800 Insurance 115,200 345,700 Legal 12,100 10,000 Other 80,500 41,200 Total $ 207,800 $ 426,900

Fixed Assets (Tables)

Fixed Assets (Tables)	9 Months Ended
	Mar. 31, 2019
Property, Plant and Equipment [Abstract]
Schedule of fixed assets, net of accumulated depreciation	Useful lives March 31, June 30, Computer and software 3 years $ 16,700 $ 16,700 Less: accumulated depreciation (8,400 ) (4,600 ) Fixed assets $ 8,300 $ 12,100

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Mar. 31, 2019
Payables and Accruals [Abstract]
Schedule of accrued expenses	March 31, June 30, Research and development $ 9,700 $ 10,400 Professional fees 132,900 173,600 Interest on promissory notes - 371,600 Accrued vacation 77,800 48,000 Litigation settlement, net 750,000 - Other 50,600 55,900 Total $ 1,021,000 $ 659,500

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	9 Months Ended
	Mar. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of assumptions used in valuation model	June 30, 2018 Common stock issuable upon exercise of warrants 2,574,570 Market value of common stock on measurement date $ 1.01 Exercise price $7.50 and $11.25 Risk free interest rate (1) 2.33 % Expected life in years $ 0.95 Expected volatility (2) 102 % Expected dividend yields (3) None (1) The risk-free interest rate was determined by management using the applicable Treasury Bill as of the measurement date. (2) The historical trading volatility was determined by calculating the volatility of the Company's stock. (3) The Company does not expect to pay a dividend in the foreseeable future.
Schedule of fair value on a recurring basis	Markets for Other Significant Carrying Description (Level 1) (Level 2) (Level 3) 2018 Derivative liability – warrant instruments $ - $ - $ 30,526 $ 30,526 Derivative liabilities – embedded redemption feature of promissory notes - - 4,164,108 4,164,108 $ - $ - $ 4,194,634 $ 4,194,634
Schedule of reconciliation of changes in the fair value of financial liabilities	Nine months ended March 31, March 31, 2019 2018 Beginning balance $ 4,194,634 $ 175,853 Adoption of ASU 2017-11 – warrants (59,397 ) - Fair value of derivative liabilities for redemption feature of promissory notes payable - 3,862,095 Change in fair value of derivative liabilities 54,634 (80,542 ) Extinguishment of derivative liabilities on conversion of promissory notes. (4,189,871 ) - Ending balance $ - $ 3,957,406

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Mar. 31, 2019
Stockholders' Equity Note [Abstract]
Schedule of private placements of securities pursuant to unit purchase agreements and subscription agreements	Date of closing Common Stock Issued Warrants issued Unit Price Net proceeds October 12, 2018 2,004,106 1,302,669 $ 0.90 $ 1,630,991 October 18, 2018 1,640,334 1,066,218 $ 0.90 $ 1,287,007 November 2, 2018 1,499,456 974,645 $ 0.90 $ 1,215,242 December 5, 2018 1,338,775 870,200 $ 0.90 $ 1,083,307 February 12, 2019 805,554 523,610 $ 0.90 $ 725,000 Total 7,288,225 4,737,342 $ 5,941,547
Schedule of changes in options outstanding	Number Weighted Average Exercise Price For Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Outstanding and expected to vest at June 30, 2018 3,068,865 $ 1.45 8.8 $ 511,000 Forfeited (25,625 ) $ 7.59 - $ - Issued 2,700,000 $ 1.15 9.7 $ 1,674,000 Outstanding and expected to vest at March 31, 2019 5,743,240 $ 1.28 8.9 $ 4,199,110 Options exercisable at March 31, 2019 1,278,687 $ 2.22 7.6 $ 799,763
Schedule of changes in outstanding warrants	Number of Shares Weighted Average Exercise Price Per Share Outstanding and vested at June 30, 2018 9,815,025 $ 3.96 Forfeited (7,500 ) 4.00 Issued 6,240,247 1.46 Outstanding and vested at March 31, 2019 16,047,772 $ 2.15
Schedule of stock-based compensation expense	Nine months ended March 31, Nine months ended March 31, Research and development $ 65,700 $ 44,500 General and administrative 744,800 320,700 Total $ 810,500 $ 365,200

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of contractual obligations	Total Less than 1 - 2 years 3 - 5 years More than Office lease $ 67,500 $ 67,500 $ - $ - $ - Note payable 28,800 28,800 - - - Total obligations $ 96,300 $ 96,300 $ - $ - $ -

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - shares	9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Summary of anti-dilutive securities
Total	21,791,015	12,389,265
Stock options [Member]
Summary of anti-dilutive securities
Total	5,743,240	2,573,240
Common stock warrants [Member]
Summary of anti-dilutive securities
Total	16,047,775	9,816,025

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details Textual) - USD ($)	9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Jun. 30, 2018
Summary of Significant Accounting Policies (Textual)
Negative operating cash flows	$ (6,830,774)	$ (3,735,905)
Accumulated deficit	$ (107,539,775)		$ (94,344,307)
Furniture and fixtures [Member]
Summary of Significant Accounting Policies (Textual)
Fixed assets, estimated useful life	7 years
Computers and software [Member]
Summary of Significant Accounting Policies (Textual)
Fixed assets, estimated useful life	3 years

Prepaid Expenses (Details)

Prepaid Expenses (Details) - USD ($)	Mar. 31, 2019	Jun. 30, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Rent		$ 9,200
Research and development		20,800
Insurance	115,200	345,700
Legal	12,100	10,000
Other	80,500	41,200
Total	$ 207,800	$ 426,900

Fixed Assets (Details)

Fixed Assets (Details) - USD ($)	9 Months Ended
	Mar. 31, 2019	Jun. 30, 2018
Computer and software	$ 16,700	$ 16,700
Less: accumulated depreciation	(8,400)	(4,600)
Fixed assets	$ 8,298	$ 12,080
Computer and software [Member]
Useful lives	3 years

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Mar. 31, 2019	Jun. 30, 2018
Payables and Accruals [Abstract]
Research and development	$ 9,700	$ 10,400
Professional fees	132,900	173,600
Interest on promissory notes		371,600
Accrued vacation	77,800	48,000
Litigation settlement, net	750,000
Other	50,600	55,900
Total	$ 1,021,000	$ 659,500

Notes Payable (Details)

Notes Payable (Details) - USD ($)	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2019
Notes Payable (Textual)
Note payable, conjunction of director and officer	$ 285,200
Note payable, interest rate per annum	2.35%
Note payable, outstanding balance	$ 285,200	$ 28,800
Note payable, maturity date	Apr. 9, 2019

Derivative Liabilities (Details

Derivative Liabilities (Details)	12 Months Ended
	Jun. 30, 2018$ / sharesshares
Summary of assumptions used in valuation model of derivatives liabilities
Common stock issuable upon exercise of warrants | shares	2,574,570
Market value of common stock on measurement date	$ 1.01
Risk free interest rate	2.33%	[1]
Expected life in years	11 months 12 days
Expected volatility	102.00%	[2]
Expected dividend yields		[3]
Minimum [Member]
Summary of assumptions used in valuation model of derivatives liabilities
Exercise price	$ 7.50
Maximum [Member]
Summary of assumptions used in valuation model of derivatives liabilities
Exercise price	$ 11.25
[1]	The risk-free interest rate was determined by management using the applicable Treasury Bill as of the measurement date.
[2]	The historical trading volatility was determined by calculating the volatility of the Company's stock.
[3]	The Company does not expect to pay a dividend in the foreseeable future.

Derivative Liabilities (Detai_2

Derivative Liabilities (Details 1) - USD ($)	Mar. 31, 2019	Jun. 30, 2018
Schedule of fair value, financial liabilities measured on recurring basis
Derivative liability		$ 4,194,634
Embedded redemption feature of promissory notes [Member]
Schedule of fair value, financial liabilities measured on recurring basis
Derivative liability		4,164,108
Warrant instruments [Member]
Schedule of fair value, financial liabilities measured on recurring basis
Derivative liability		30,526
Markets for Identical Assets (Level 1) [Member]
Schedule of fair value, financial liabilities measured on recurring basis
Derivative liability
Markets for Identical Assets (Level 1) [Member] | Embedded redemption feature of promissory notes [Member]
Schedule of fair value, financial liabilities measured on recurring basis
Derivative liability
Markets for Identical Assets (Level 1) [Member] | Warrant instruments [Member]
Schedule of fair value, financial liabilities measured on recurring basis
Derivative liability
Other Observable Inputs (Level 2) [Member]
Schedule of fair value, financial liabilities measured on recurring basis
Derivative liability
Other Observable Inputs (Level 2) [Member] | Embedded redemption feature of promissory notes [Member]
Schedule of fair value, financial liabilities measured on recurring basis
Derivative liability
Other Observable Inputs (Level 2) [Member] | Warrant instruments [Member]
Schedule of fair value, financial liabilities measured on recurring basis
Derivative liability
Significant Unobservable Inputs (Level 3) [Member]
Schedule of fair value, financial liabilities measured on recurring basis
Derivative liability		4,194,634
Significant Unobservable Inputs (Level 3) [Member] | Embedded redemption feature of promissory notes [Member]
Schedule of fair value, financial liabilities measured on recurring basis
Derivative liability		4,164,108
Significant Unobservable Inputs (Level 3) [Member] | Warrant instruments [Member]
Schedule of fair value, financial liabilities measured on recurring basis
Derivative liability		$ 30,526

Derivative Liabilities (Detai_3

Derivative Liabilities (Details 2) - Significant Unobservable Inputs (Level 3) [Member] - USD ($)	9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Fair Value Input Liabilities Quantitative Information [LineItems]
Beginning balance	$ 4,194,634	$ 175,853
Adoption of ASU 2017-11 – warrants	(59,397)
Fair value of derivative liabilities for redemption feature of promissory notes payable		3,862,095
Change in fair value of derivative liabilities	54,634	(80,542)
Extinguishment of derivative liabilities on conversion of promissory notes.	(4,189,871)
Ending balance		$ 3,957,406

Derivative Liabilities (Detai_4

Derivative Liabilities (Details Textual)	1 Months Ended
	Jul. 02, 2018USD ($)
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Adjusted balance of reversed to equity	$ 59,397

Promissory Notes Payable (Detai

Promissory Notes Payable (Details) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	Oct. 31, 2018	Dec. 31, 2018	Mar. 31, 2019
Promissory Notes Payable (Textual)
Notes converted into shares of common stock	10,731,699
Loss on extinguishment of debt		$ 3,774,500
Between September 2017 and January 2018 [Member]
Promissory Notes Payable (Textual)
Aggregate gross proceeds of convertible notes payable			$ 7,205,000
Debt issuance costs, net			$ 6,534,400
Interest rate			7.00%

Stockholders' Equity (Details)

Stockholders' Equity (Details)	9 Months Ended
	Mar. 31, 2019USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock Issued	$ 7,288,225
Warrants issued | shares	4,737,342
Net proceeds	$ 5,941,547
October 12, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock Issued	$ 2,004,106
Warrants issued | shares	1,302,669
Unit Price | $ / shares	$ 0.90
Net proceeds	$ 1,630,991
October 18, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock Issued	$ 1,640,334
Warrants issued | shares	1,066,218
Unit Price | $ / shares	$ 0.90
Net proceeds	$ 1,287,007
November 2, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock Issued	$ 1,499,456
Warrants issued | shares	974,645
Unit Price | $ / shares	$ 0.90
Net proceeds	$ 1,215,242
December 5, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock Issued	$ 1,338,775
Warrants issued | shares	870,200
Unit Price | $ / shares	$ 0.90
Net proceeds	$ 1,083,307
February 12, 2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock Issued	$ 805,554
Warrants issued | shares	523,610
Unit Price | $ / shares	$ 0.90
Net proceeds	$ 725,000

Stockholders' Equity (Details 1

Stockholders' Equity (Details 1) - Employee Stock Option [Member] - USD ($)	9 Months Ended	12 Months Ended
	Mar. 31, 2019	Jun. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Outstanding and expected to vest, Beginning balance	3,068,865
Number of Options, Forfeited	(25,625)
Number of Options, Issued	2,700,000
Number of Options, Outstanding and expected to vest, Ending balance	5,743,240	3,068,865
Number of Options, exercisable	1,278,687
Weighted Average Exercise Price For Share, Outstanding and expected to vest - Beginning balance	$ 1.45
Weighted Average Exercise Price Per Share, Forfeited	7.59
Weighted Average Exercise Price Per Share, Issued	1.15
Weighted Average Exercise Price Per Share, Outstanding and expected to vest - Ending balance	1.28	$ 1.45
Weighted Average Exercise Price Per Share, Options exercisable	$ 2.22
Weighted Average Remaining Contractual Term (Years), Outstanding and expected to vest	9 years 1 month 6 days	8 years 9 months 18 days
Weighted Average Remaining Contractual Term (Years), Issued	8 years 10 months 25 days
Weighted Average Remaining Contractual Term (Years), Options exercisable	7 years 7 months 6 days
Aggregate Intrinsic Value, Outstanding and expected to vest - Beginning balance	$ 511,000
Aggregate Intrinsic Value, Options Issued	1,674,000
Aggregate Intrinsic Value, Outstanding and expected to vest - Ending balance	4,199,110	$ 511,000
Aggregate Intrinsic Value, Options exercisable	$ 799,763

Stockholders' Equity (Details 2

Stockholders' Equity (Details 2) - Stock-based compensation - warrants [Member]	9 Months Ended
	Mar. 31, 2019$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding and vested, Beginning balance | shares	9,815,025
Number of Shares, Forfeited | shares	(7,500)
Number of Shares, Issued | shares	6,240,247
Number of Shares, Outstanding and vested, Ending balance | shares	16,047,772
Weighted Average Exercise Price Per Share, Outstanding and vested, Beginning balance | $ / shares	$ 3.96
Weighted Average Exercise Price Per Share, Forfeited | $ / shares	4
Weighted Average Exercise Price Per Share, Issued | $ / shares	1.46
Weighted Average Exercise Price Per Share, Outstanding and vested, Ending balance | $ / shares	$ 2.15

Stockholders' Equity (Details 3

Stockholders' Equity (Details 3) - USD ($)	9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 810,500	$ 365,200
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	65,700	44,500
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 744,800	$ 320,700

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($)

Mar. 27, 2019

Mar. 09, 2019

Jan. 02, 2019

Oct. 12, 2018

Dec. 31, 2018

Dec. 20, 2018

Oct. 18, 2018

Feb. 28, 2018

Jan. 31, 2017

Dec. 31, 2014

Mar. 31, 2019

Jun. 30, 2018

Stockholders' Equity (Textual)

Aggregate common stock issued

$ 7,288,225

Net proceeds

$ 5,941,547

Percentage of convertible promissory notes

7.00%

7.00%

Converted shares of common stock

10,731,669

10,731,669

Warrants exercise price

$ 0.99

Options [Member]

Stockholders' Equity (Textual)

Number of options granted

2,700,000

4,111,768

1,611,769

Stock options exercisable period

10 years

10 years

Number of shares available for future grants under stock option plan

4,868,528

Options exercise price

$ 1.15

Vesting period

4 years

4 years

Shares authorized to be issued

2,500,000

2,500,000

Aggregate fair value of options

$ 2,500,000

Discount rate

2.69%

Expected life term

6 years 2 months 30 days

Expected volatility rate

102.30%

Expected dividends rate

0.00%

Stock-based compensation expense

$ 3,448,900

Weighted average remaining service period

3 years 4 months 6 days

Common stock authorized for issuance

4,000,000

Options [Member] | Minimum [Member]

Stockholders' Equity (Textual)

Number of options granted

4,111,768

Common stock authorized for issuance

6,611,768

Options [Member] | Maximum [Member]

Stockholders' Equity (Textual)

Number of options granted

6,611,768

Common stock authorized for issuance

10,611,768

Options [Member]

Stockholders' Equity (Textual)

Number of options granted

2,700,000

Weighted average fair value of options granted

$ 1.15

Aggregate intrinsic value of warrants outstanding

$ 4,057,000

$ 215,000

Weighted average remaining service period

7 years 7 months 6 days

Warrants [Member]

Stockholders' Equity (Textual)

Number of options granted

71,429

120,000

100,000

Stock options exercisable period

5 years

10 years

10 years

Options exercise price

$ 1.75

$ 1.15

$ 1.15

Weighted average fair value of options granted

$ 1.50

Aggregate fair value of options

$ 95,131

$ 112,183

$ 93,762

Discount rate

2.42%

2.49%

2.69%

Expected life term

5 years

6 years 2 months 30 days

6 years 2 months 30 days

Expected volatility rate

102.00%

102.30%

102.30%

Expected dividends rate

0.00%

0.00%

0.00%

Warrants issued

$ 357,142

Warrants exercise price

$ 2.25

1.50

Price per unit

$ 0.90

Term of warrant

5 years

Common stock issuable upon exercise of warrants

2,574,570

2,574,570

Legal costs

$ 40,000

Warrants [Member] | Placement agent [Member]

Stockholders' Equity (Textual)

Warrants issued

$ 854,334

Warrants exercise price

$ 0.99

Term of warrant

5 years

Common Stock and Warrant [Member]

Stockholders' Equity (Textual)

Price per unit

$ 0.65

Unit Purchase Agreements and Subscription Agreements [Member]

Stockholders' Equity (Textual)

Common stocks issued

714,285

Net proceeds

$ 1,000,000

Price per unit

$ 1.40

Unit Purchase Agreements and Subscription Agreements [Member] | Common Stock and Warrant [Member]

Stockholders' Equity (Textual)

Price per unit

$ 0.50

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	Jun. 12, 2017	Jun. 30, 2015
Related Party Transactions (Textual)
Consulting fee	$ 10,000
Consulting agreement term	1 year
Sandesh Seth [Member]
Related Party Transactions (Textual)
Advisory services fee		$ 12,500

Commitments and Contingencies_2

Commitments and Contingencies (Details)	Mar. 31, 2019USD ($)
Other Commitments [Line Items]
Contractual obligations due less than 1 year	$ 96,300
Contractual obligations due in 1-2 years
Contractual obligations due in 3-5 years
Contractual obligations due in more than 5 years
Total obligations	96,300
Office lease [Member]
Other Commitments [Line Items]
Contractual obligations due less than 1 year	67,500
Contractual obligations due in 1-2 years
Contractual obligations due in 3-5 years
Contractual obligations due in more than 5 years
Total obligations	67,500
Note payable [Member]
Other Commitments [Line Items]
Contractual obligations due less than 1 year	28,800
Contractual obligations due in 1-2 years
Contractual obligations due in 3-5 years
Contractual obligations due in more than 5 years
Total obligations	$ 28,800

Commitments and Contingencies_3

Commitments and Contingencies (Details Textual) - USD ($)	1 Months Ended		9 Months Ended
	Feb. 06, 2019	Jun. 08, 2017	Mar. 31, 2019
Commitments and Contingencies (Textual)
Unearned interest income			$ 48,900
Settlement Agreement [Member]
Commitments and Contingencies (Textual)
Relinquished shares	303,392
Initial payment	$ 500,000
Settlement Agreement [Member] | March 31, 2019 [Member]
Commitments and Contingencies (Textual)
Subsequent payments	250,000
Settlement Agreement [Member] | June 30, 2019 [Member]
Commitments and Contingencies (Textual)
Subsequent payments	250,000
Settlement Agreement [Member] | September 30, 2019 [Member]
Commitments and Contingencies (Textual)
Subsequent payments	250,000
Settlement Agreement [Member] | December 31, 2019 [Member]
Commitments and Contingencies (Textual)
Subsequent payments	$ 250,000
Lease Agreements [Member]
Commitments and Contingencies (Textual)
Lease expiration date			Jan. 1, 2019
Rental fee			$ 9,454
Annualized monthly rent amount			$ 7,500
Licensing Agreements [Member]
Commitments and Contingencies (Textual)
Lease expiration date		Dec. 8, 2022
Lease term, description		Actinium will continue to license the furniture, fixtures, equipment and tenant improvements located in the office ("FFE") for a license fee of $7,529 per month until December 8, 2022. Actinium shall have at any time during the term of this agreement the right to purchase the FFE for $496,914, less any previously paid license fees. The license of FFE qualifies as a sales-type lease. At inception, the Company derecognized the underlying assets of $493,452, recognized discounted lease payments receivable of $397,049 using the discount rate of 8.38% and recognized loss on sales-type lease of fixed assets of $96,403.
Cost of license		$ 7,529

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	May 14, 2019	Apr. 01, 2019	Mar. 31, 2019	Apr. 15, 2019	Apr. 12, 2019	Jun. 30, 2018
Subsequent Events (Textual)
Warrants exercise price			$ 0.99
Net proceeds			$ 5,941,547
Common stock, shares authorized			200,000,000			200,000,000
Subsequent Event [Member]
Subsequent Events (Textual)
Subsequent event, Description	One agent received warrants to purchase 48,433 shares at an exercise price of $1.65 and the other agent a warrant to purchase 99,000 shares of common stock at an exercise price of $2.25. Both warrants have a term of 5 years. The warrants have aggregate fair value of $66,800 and $122,942 respectively, calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 2.26% (2) expected life of 5 years, (3) expected volatility of 101%, and (4) zero expected dividends.	The Company awarded 150,000 options to a new employee with exercise price of $1.76 and a 10-year term vesting over 4-year period. The options have an aggregate fair value of $213,803 calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 2.31% (2) expected life of 6.25 years, (3) expected volatility of 101.5%, and (4) zero expected dividends.
Authorized to issue under the plan				10,111,718
Subsequent Event [Member] | Minimum [Member]
Subsequent Events (Textual)
Common stock, shares authorized					100,000,000
Subsequent Event [Member] | Maximum [Member]
Subsequent Events (Textual)
Common stock, shares authorized					200,000,000
Subsequent Event [Member] | Unit Purchase Agreements and Subscription Agreements [Member]
Subsequent Events (Textual)
Common stocks issued	2,276,329
Warrants issued	$ 1,138,161
Warrants exercise price	$ 2.25
Warrants term	5 years
Net proceeds	$ 3,106,000
Price per unit	$ 1.50
Subsequent Event [Member] | Unit Purchase Agreements and Subscription Agreements [Member] | Common Stock and Warrant [Member]
Subsequent Events (Textual)
Price per unit	$ 0.50